Overview

In this webinar, Drs. Andrew Cutler and Stephen Stahl discuss the mechanistic and clinical profiles of recently approved antipsychotics as well as of those in late-stage and earlier clinical development.

Available Broadcasts (same content repeated at each): March 8, 10, 16, 18

Learning Objectives

• Identify novel underlying biological mechanisms of new antipsychotics
• Integrate new and soon-to-be introduced treatments into contemporary practice by combining practical experience with evolving new evidence

Target Audience
This activity has been developed for prescribers specializing in psychiatry. There are no prerequisites for this activity. Health care providers in all specialties who are interested in psychopharmacology, especially primary care physicians, nurses, psychologists, and pharmacists, are welcome for advanced study.

Statement of Need
The following unmet needs regarding treatment of schizophrenia were revealed following a critical analysis of activity feedback, expert faculty assessment, literature review, and through new medical knowledge:

• Remission rates in trials of schizophrenia drugs are generally reported lower than 50% and often as low as 25% or lower
• Recovery rates, defined as symptom remission as well as improvement in cognitive and psychosocial functioning, are even lower

To help fill these unmet needs, quality improvement efforts need to provide education regarding new treatment strategies for schizophrenia, including novel mechanisms of action, and how these new options can help fill unmet needs within the current treatment of schizophrenia.

Faculty
Stephen M. Stahl, MD, PhD
Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine
Honorary Visiting Senior Fellow, University of Cambridge, UK

Andrew J. Cutler, MD
Courtesy Assistant Professor, Dept of Psychiatry, University of Florida, Gainesville
CEO and Medical Director, Florida Clinical Research Center, LLC